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Abstract 
Hiccups are the sudden involuntary contractions of the diaphragm and intercostal muscles. They are generally benign 
and self-limited, however, in some cases they are chronic and debilitating. There are approximately 4000 admissions 
for hiccups each year in the United States. The hiccup reflex arc is composed of three components: (1) an afferent 
limb including the phrenic, vagus, and sympathetic nerves, (2) the central processing unit in the midbrain, and (3) 
the efferent limb carrying motor fibers to the diaphragm and intercostal muscles. Hiccups may be idiopathic, organic, 
psychogenic, or medication-induced. Data obtained largely from case studies of hiccups either induced by or treated 
with medications have led to hypotheses on the neurotransmitters involved. The central neurotransmitters implicated 
in hiccups include GABA, dopamine, and serotonin, while the peripheral neurotransmitters are epinephrine, norepi-
nephrine, acetylcholine, and histamine. Further studies are needed to characterize the nature of neurotransmitters at 
each anatomical level of the reflex arc to better target hiccups pharmacologically.
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Background
The term “singultus” (hiccup) comes from singult; a Latin 
word that means ‘sob’ or ‘gasp’. It refers to the sounds 
that are produced by the sudden involuntary contrac-
tions of the diaphragm and intercostal muscles followed 
by an abrupt contraction of the glottis. The air strikes the 
closed glottis and results in the characteristic “hiccup” 
sound. Hiccups are usually benign and self-limiting. They 
generally start without any specific reason and disappear 
in a few minutes. Brief episodes of hiccups are common 
in healthy individuals after a large meal, intake of alco-
holic beverages, or sudden excitement.
This article provides a review of different neurotrans-
mitters that are related in the mechanism of action of 
the most commonly used drugs to treat hiccups, and the 
medications that induced hiccups. At the end, this paper 
draws a conclusion about the neurotransmitters involved 
in the pathophysiology of hiccups.
Epidemiology
The classification of hiccups is based on their duration. 
An acute attack lasts less than forty-eight hours. Persis-
tent hiccups last more than 2  days. Intractable hiccups 
are present if the attack lasts more than 1  month. Per-
sistent hiccups are most likely to be associated with an 
underlying pathological, anatomic or organic disease 
process (Cymet 2002). Intractable hiccups that continue 
for more than 1  month are usually indicative of a seri-
ous organic disturbance (Vaidya 2000). If left untreated, 
intractable hiccups can cause severe discomfort, depres-
sion, reduced physical strength, and even death (Con-
sults 2011). According to a report by William H. Dobelle, 
approximately 4000 hospital admissions due to hiccups 
are reported each year in the United States (Dobelle 
1999). The intractable hiccups are more common in men 
(82  %) than in women. Most of the men suffering from 
hiccups are 50 years of age or older (Cymet 2002). Psy-
chogenic hiccups have been reported to occur more 
commonly in women. The usual rate for hiccups is four 
to sixty per minute with fairly constant frequency in an 
individual (Howes 2012). Pathological hiccups can be 
explained as a form of epilepsy or a failure of supra-spinal 
inhibition (Launois et  al. 1993; Lewis 1985). The inci-
dence and prevalence of persistent and intractable hic-
cups in the community has not been studied.
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Pathophysiology
The pathophysiological mechanism of hiccups is related 
to lesions in its reflex arc as shown in Fig. 1. The reflex arc 
is comprised of three components:
1. The afferent limb including phrenic, vagus, and sym-
pathetic nerves to pass on somatic and visceral sen-
sory signals;
2. The central processing unit in the midbrain; and
3. The efferent limb travelling in motor fibers of phrenic 
nerve to diaphragm and accessory nerves to the 
intercostal muscles, respectively.
The central component is located in the periaque-
ductal grey, subthalamic nuclei (Hansen and Rosenberg 
1993) among the brain stem respiratory center, phrenic 
nerve nuclei, reticular formation and hypothalamus. 
The central component for hiccups lies in the medulla 
and is thought to be entirely separate from the pathways 
involved in rhythmic breathing (Davis 1970). Dopamine, 
gamma-amino-butyric-acid (GABA), serotonin, gluta-
mate, and glycine neurotransmitters can regulate this 
central mechanism. The hiccup arc has modulatory input 
from catecholaminergic and serotonergic afferents.
The release of 5-hydroxyl-tryptamine (5HT) from the 
gut enterochromaffin cells and enteric vagal afferents 
may also lead to hiccups as seen in a case report following 
administration of cisplatinum, a chemotherapeutic agent 
(Jatoi 2009). The mental branch of the trigeminal nerve 
was also postulated to develop hiccups when stimulated 
via chin shaving (Todisco et  al. 2004). Significant nega-
tive intrathoracic pressure may occur during hiccups that 
may result in hypotension, bradycardia, pneumomedi-
astinum, and subcutaneous emphysema (Rousseau 1995). 
The mechanism of action of hiccups might be mediated 
through agonizing 5-HT1A and antagonizing 5-HT2A 
receptors to enhance the activity of the phrenic nerve, 
thereby inducing hiccups. This concept was supported in 
Fig. 1 Hiccup reflex arc with neurotransmitters
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a case report in which quetiapine was successfully used 
to resolve the aripirazole-induced hiccups. This may sug-
gest the partial agonist and relatively high 5-HT1A recep-
tors binding affinities in the pathophysiology of hiccups 
(Gilson and Busalacchi 1998). It is postulated in a study 
that the GABA-containing cells in the nucleus raphe 
are the source of GABA-nergic inhibition of the hiccup 
center (Musumeci et al. 2000).
The most commonly used pharmacological treatments 
include metoclopramide which reduces the intensity of 
esophageal contraction, chlorpromazine (Twycross et al. 
2002), baclofen, nifedipine which reverses the abnor-
mal depolarization in the hiccups reflex, valproic acid 
that enhances GABA transmission centrally (Smith and 
Busracamwongs 2003), antipsychotics, glucagon, GABA 
analogue which acts by activating an inhibitory neuro-
transmitter, and dimethlamine derivative of phenothia-
zine which acts centrally by dopamine blockade in the 
hypothalamus (Friedman 1996). Baclofen (GABA-ago-
nist) is among the substances that act through the nerv-
ous system and has by far the best ability to treat chronic 
hiccups (Guelaud et al. 1995; Oshima et al. 1998; Petroi-
anu et al. 1997; Steger et al. 2015). However, a Cochrane 
systemic review found insufficient evidence as to which 
pharmacological agent is best for hiccups (Moretto et al. 
2013). Hiccups are the manifestation of diaphragmatic 
myoclonus and are considered to be a form of physiologic 
myoclonus.
Etiology
In the review of recent literature, a variety of hiccups 
etiologies have been reported (idiopathic, organic, psy-
chogenic, and medication-induced) induced have been 
reported. Table 1 provides an overview of pathology that 
has been reliably linked to this condition. It has been sug-
gested that damage to the cervical cord, brainstem, hypo-
thalamus, and supra-tentorial area precipitate hiccups by 
stimulating the hiccups reflex arc or decreasing the nor-
mal inhibition of hiccup neurons. It is suggested that all 
potentially successful therapeutic drugs used to treat hic-
cups either decrease the input from gastrointestinal tract 
(GIT) to the hiccups center or decrease the excitability 
and output from the hiccups center (Burke et  al. 1988; 
Petroianu et al. 1997).
Neurotransmitters targets in hiccups
The exact etiology of hiccups is unclear, and it is 
unknown why diverse drugs like dopamine blocking 
agents (DBA), baclofen, clonazepam, and phenytoin, 
which have widely varying mechanisms of action, can 
be effective in the treatment of hiccups (Peleg and Peleg 
2000). Table 2 summarize drugs which induce and treat 
hiccups and their potential neurotransmitters.
Gama‑amino butyric acid (GABA)
There is strong evidence that the GABA is one of the 
neurotransmitters involved in the hiccups reflex at the 
central level. GABA functions as an inhibitory media-
tor at the interneuron level in the brain and in the spinal 
cord (presynaptic inhibition) by altering trans-membrane 
potential. Glutamic acid is decarboxylated to produce 
GABA by the enzyme l-glutamate decarboxylase (Rod-
well 2012). The inhibition of synapses by GABA has been 
shown in the cerebellar cortex, hippocampus, olfactory 
bulb, cuneate nucleus, caudate nucleus, substantia nigra, 
septal nucleus, and between the vestibular and trochlear 
Table 1 Common causes of hiccups
Central nervous system Vascular Stroke, Infarct, SLE related vascular disorders and aneurysm
Infectious Meningitis and Encephalitis
Structural Brain injury, Intracranial tumors
Inflammation Neuromyelitis optica and multiple sclerosis
Miscellaneous Seizure, Parkinson’s Syndrome
Peripheral Nervous System (phrenic, vagal  
and sympathetic nerves)
Gastrointestinal Hiatus hernia, Esophageal cancer, Gastro-esophageal reflex 
disease, stomach volvulus and H.pylori infection, Pancreatitis, 
Abdominal abscess and Abdominal tumors
Thoracic Cardiovascular Myocardial Ischemia, Pericarditis, Thoracic Aneurysm
Pulmonary Bronchitis, Pneumonia, Asthma, Bronchial carcinoma, Tuberculosis
Ear, Nose and Throat Rhinitis, Otitis, Pharyngitis, Foreign body in nose or ear
Other causes Toxic metabolic Electrolyte imbalance, Alcohol, Chronic renal failure, Diabetes 
mellitus
Pharmacological Steriods, benzodiazepines, chlordiazepoxide, diazepam, antibiot-
ics, sulfonamides, opioids, cisplatinum (Jatoi 2009), analeptic 
agent, Methyldopa, l-dopa, Dopamine
Psychosomatic Anxiety, sleep deprivation, stress and fear
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motor neurons. There are three main types of GABA 
receptors—GABA-A, -B, and -C. GABA-A are the most 
abundant receptors and the site of action of many neuro 
active drugs such as benzodiazepines, barbiturates, etha-
nol and volatile anesthetics (Molinoff 2011). Valproic 
acid enhances GABA transmission centrally (Smith and 
Busracamwongs 2003) and is one of the most commonly 
suggested therapies for hiccups. It is postulated in a study 
that the GABA-containing cells in the nucleus raphe are 
the source of GABA-ergic inhibition of the hiccup center 
(Musumeci et al. 2000).
Dopamine
There are many studies to support the convincing role 
of dopamine as the central neurotransmitter involved 
in hiccup pathogenesis. Dopamine is found in the brain 
and peripherally in the adrenal medulla, plexuses of the 
GI tract, and the enteric nervous system. Dopamine is 
an adrenergic agonist that is non-selective (Morgan et al. 
2005). There are five dopamine receptor subtypes that 
have been delineated by pharmacological analysis that 
are the bases of a subtype of selective drugs. There are 
three major dopaminergic pathways in the central nerv-
ous system:
1. the niagrostriatal pathway which is important in Par-
kinson’s disease;
2. the mesolimbic pathway which plays a role in psychi-
atric disorders; and
3. the tuberoinfundibular pathway, which is related to 
the regulation of the endocrine system.
Dopamine is an immediate precursor of norepineph-
rine. The synthesis of dopamine can be increased by 
giving DOPA (Smith and Busracamwongs 2003; Ash-
ley and Krych 1995). There are many studies, in which 
patients have been treated successfully by using dopa-
mine blocking drugs such as metochlopromide and 
chlorpromazine (Smith and Busracamwongs 2003) which 
supports the evidence that dopamine acts as the central 
neurotransmitter.
5‑Hydroxyl tryptamine (5HT; serotonin)
Many studies support the role of 5HT (serotonin) as the 
neurotransmitter of hiccups. Serotonin is an important 
central nervous system neurotransmitter and a local hor-
mone. It is also found in high concentrations in entero-
chromaffin cells throughout the GIT that are the site of 
synthesis and storage of 5 HT from tryptophan. It regu-
lates the smooth muscles in the GIT to increase the tone 
and facilitate the peristalsis via 5HT2 receptors (Katzung 
2012). It is a powerful vasoconstrictor mainly through 
5HT2 receptor but it dilates the blood vessels of the 
heart and skeletal muscles (Katzung 2012). It is produced 
in two steps: in step 1, tryptophan in converted to 5HT 
and in the next step, the 5HT is converted to serotonin. 
Increasing the concentration of tryptophan in the brain 
can increase the high concentration of 5HT and sero-
tonin. Drugs that increase serotonin levels were most 
commonly used as appetite suppressants. They regulate 
the smooth muscles in the GIT and cardiovascular sys-
tem. There are fourteen subtypes of receptor of 5HT 
recognized. There are the 5HT1 subfamily and 5HT2 
subfamilies of receptors. 5HT3 subfamilies were origi-
nally described in the periphery. There are fourteen sub-
types of receptor of 5HT recognized. Cases of intractable 
hiccups have been successfully treated with olanzapine 
(Alderfer and Arciniegas 2006). Olanzapine has a com-
plex pharmacology and its major effect is to antago-
nize the postsynaptic serotonergic receptors. Similarly, 
another case was reported describing the successful 
treatment of hiccups with sertraline, a selective seroto-
nin reuptake inhibitor (SSRI), for the first time (Benowitz 
2012; Vaidya 2000). In one case study, intractable hic-
cups were treated successfully with a tandospirone, a new 
anxiolytic and 5HTA1 receptor agonist (Takahashi et al. 
2004). Interestingly, a case report of intractable hiccups 
that was refractory to the typical antipsychotic haloperi-
dol, however, responsive to atypical antipsychotic risp-
eridone which acts on 5HT2A, 5HT1A, 5HT1C, 5HT1D, 
and D2 receptors (Nishikawa et al. 2015). All these stud-
ies are evidence that serotonin is involved in the patho-
physiology of hiccups.
Histamine
Histamine is produced by decarboxylation of histadine, 
an amino acid, by the enzyme histadine decarboxylases 
(Biomedical Aspects of Histamine 2011).
Histamine is released by the various triggers from mast 
cells and basophils and has various biological effects 
through four receptors H1R, H2R, H3R, H4R. Hista-
mine causes smooth cell contractions, vasodilatation, 
and gastric acid secretion. Hyperhistaminemia can cause 
an anaphylactic reaction (Hershko et  al. 2001). There is 
evidence for the use of H2-receptor blockers and proton 
pump inhibitors (i.e. omeprazole) for the treatment of 
hiccups thought to act via decreasing the input from the 
GIT to the hiccup center (Petroianu et al. 1997).
Epinephrine and norepinephrine (NE)
Noreepinephrine (NE) is the neurotransmitter of the 
post ganglionic autonomic nervous system that is 
involved in the reduction of gastrointestinal motility. 
NE is synthesized from tyrosine that is produced from 
phenyle alanine. Dopamine is converted to NE by dopa-
mine beta hyroxylases. Norepinephrine is converted 
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to epinephrine by the enzyme phenyle ethanolamine-
N-methyltransferase. The action of neurotransmit-
ter catecholamines is terminated by the re-uptake 
and metabolism by the enzymes monoamine oxidases 
(MOA) and catecolaminotransferases (COMT). The 
inhibitors of these enzymes are used in the treatment 
of Parkinson’s disease. Adreno receptors have four sub-
types, alpha1, alpha2, and beta1 for NE mainly and B2 
is for epinephrine mainly. There are studies about the 
successful treatment of hiccups with methylphenidate 
(a psycho-stimulant) generally used in attention deficit 
disorders (Marechal et al. 2003; Pollock et al. 2009). The 
methylphenidate is considered as the receptor modula-
tor of dopamine and norepinephrine. Therefore relation-
ship may exist between norepinephrine and epinephrine 
to the pathophysiology of hiccups.
Acetylcholine
Acetylcholine is a naturally occurring neurotransmit-
ter for the muscarinic receptors. It is a neurotransmitter 
of all the preganglionic autonomic fibres, most post-
ganglionic parasympathetic, and a few post-ganglionic 
sympathetic fibers (Westfall and Westfall 2011). Meto-
clopramide, an anticholinergic, is recommended for the 
symptomatic relief of hiccups. There are studies that 
show that metoclopramide acts peripherally to reduce 
the intensity of esophageal contraction (Consults 2011). 
It has also been observed that metoclopramide have been 
used to treat hiccups (Smith and Busracamwongs 2003) 
which may explain the relation of acetylcholine as the 
peripheral neurotransmitter involved in the pathophysi-
ology of hiccups.
Conclusion
Largely through case studies involving medications, we 
implicate the neurotransmitters involved in hiccups. The 
reflex arc is potentially mediated by central neurotrans-
mitters (GABA, dopamine, and serotonin) and peripheral 
neurotransmitters (epinephrine, norepinephrine, acetyl-
choline, and histamine). Lesions across any of these neu-
roanatomical structures, for instance, from the brainstem 
down to the diaphragm, may be responsible for the devel-
opment of hiccups. Further research is needed to char-
acterize the neurotransmitters involved in hiccups for 
potential new therapeutic targets.
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